Clinical trials: Hepatic Tumor
Hepatocellular Carcinoma
A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)
Radiation-induced liver disease (RILD) is a syndrome characterized by the development of anicteric ascites approximately 2 weeks to 4 months after hepatic irradiation.
- Trial name
- NCT01519232
- Testing
- Liver Irradiation
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan Rogel Cancer Center
Hepatocellular Carcinoma, Scirrhous, Recurrence Tumor
HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma
Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in cirrhosis. Due to organs shortage, the proper selection of patients is imperative.
- Trial name
- HepatoPredict (NCT04499833)
- Testing
- liver transplant
- Where
- Portugal
- Volunteers
- 40 people
- Sponsor
- Centro Hospitalar de Lisboa Central
Hepatocellular Carcinoma
CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis
The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.
- Trial name
- NCT04512833
- Testing
- Cyberknife stereotactic body radiation therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing 302 Hospital
Primary Liver Carcinoma
Laparoscopic Hepatectomy Versus Open Hepatectomy for PHC
The purpose of this study is to compare short-term and long-term efficacy of laparoscope hepatectomy and open hepatectomy, evaluate the safety and efficacy of laparoscope hepatectomy the PHC with a tumor size of 5～10㎝,and provide…
- Trial name
- NCT02014025
- Testing
- Open hepatectomy, Laparoscope hepatectomy
- Where
- China
- Volunteers
- 335 people
- Sponsor
- Shuguo Zheng, MD
Advanced Hepatocellular Carcinoma
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
- Trial name
- SIERRA (NCT05883644)
- Testing
- Durvalumab, Tremelimumab
- Where
- 40 sites in United States, France and 8 more
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
Surefire Institutional DEB-TACE
The purpose of this study is to determine the feasibility and safety of the Surefire Infusion System (SIS) for delivery of Drug Eluting Beads Transcatheter Chemoembolization (DEB-TACE) in the HCC population.
- Trial name
- NCT03211598
- Testing
- TACE with Surefire
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Alexander Kim
Hepatocellular Carcinoma
Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
This study represents a phase I clinical trial that utilizes natural killer (NK) cell therapy for patients diagnosed with liver cancer, specifically those classified as Child-Pugh A and falling within the Barcelona Clinic Liver…
- Trial name
- NCT06044506
- Testing
- Autologous Natural Killer Cell Therapy, Clinimacs Plus
- Where
- Indonesia
- Volunteers
- 3 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Advanced Cancers
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
The goal of this clinical research study is to find the highest tolerable dose of the combination of oxaliplatin and capecitabine with or without bevacizumab that can be given to patients with advanced cancer that has spread to…
- Trial name
- NCT01213238
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Cirrhosis and Hepatoma., Gastric Variceal Bleeding
Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding
Gastric variceal bleeding has a very high rebleeding rate even after endoscopic variceal injection of cyanoacrylate (GVO) which is considered the first choice of endoscopic treatment.
- Trial name
- GVO-nadolol (NCT00567216)
- Testing
- Nadolol
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Localized Malignant Solid Neoplasm, Anal Cancer
Distance-Based Exercise to Preserve Function and Prevent Disability
This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home.
- Conditions
- Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer
- Trial name
- DEFEND (NCT07059884)
- Testing
- Exercise intervention, Telemedicine, Aerobic Exercise Intervention
- Where
- 23 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Liver Carcinoma, Hepatic Cell Carcinoma
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infused autologous GPC3-directed CAR-T in patients with advanced hepatocellular carcinoma refractory to prior systematic…
- Trial name
- NCT06144385
- Testing
- CAR-GPC3 T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Solid Tumor, Lung Cancer
Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
This is a single arm study to evaluate the efficacy and safety of CEA-targeted CAR-T cells therapy for patients with relapsed/refractory CEA+ Cancer,and obtain the recommended dose and infusion plan.
- Conditions
- Solid Tumor, Lung Cancer, Colorectal Cancer, Liver Cancer
- Trial name
- NCT04348643
- Testing
- CEA CAR-T cells
- Where
- 2 sites in China
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Advanced Hepatocellular Carcinoma
A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma
This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells by hepatic artery infusions in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT03993743
- Testing
- CD147-CART
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Xijing Hospital
Hepatocellular Carcinoma
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of care therapy (sorafenib) in the treatment of…
- Trial name
- YES-P (NCT01887717)
- Testing
- TheraSphere®, Sorafenib
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Liver Neoplasm
Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors
Microwave ablation is a minimally invasive technique whose planning relies on manufacturer tables derived from ex vivo models that do not account for patient or tumor-specific factors.
- Trial name
- MICRO-VAR (NCT07413640)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Central Hospital, Nancy, France
Non-small Cell Lung Cancer, Gastric Cancer
A Study of CDX-585 in Patients With Advanced Malignancies
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT05788484
- Testing
- CDX-585
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Celldex Therapeutics
Hepatocellular Carcinoma, Cancer of Liver
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
This trial will assess the safety and tolerability of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab in unresectable or metastatic hepatocellular carcinoma.
- Trial name
- NCT05109052
- Testing
- PXS-5505 and Atezolizumab and Bevacizumab
- Where
- United States
- Sponsor
- University of Rochester
Hepatocellular Carcinoma
Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events
To collect tumor tissue from patients with liver masses suspicious for primary liver cancer. The research biopsy will be used to identify biomarkers in future studies.
- Trial name
- NCT01963949
- Sponsor
- University of Texas Southwestern Medical Center
Hepatocellular Carcinoma
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Researchers are looking for a better way to treat people diagnosed with liver cancer which may have spread to nearby tissue and is unlikely to be cured or controlled with treatment (advanced metastatic hepatocellular carcinoma…
- Trial name
- NCT04696055
- Testing
- Pembrolizumab, Regorafenib (Stivarga, BAY73-4506)
- Where
- 39 sites in United States, France and 6 more
- Volunteers
- 95 people
- Sponsor
- Bayer
Hemostasis in Decompensated Liver Cirrhosis, Inflammation in Decompensated Liver Cirrhosis
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
- Trial name
- HELICS (NCT06212635)
- Testing
- T-TAS
- Where
- Sweden
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Region Stockholm